Summary of Track A: Basic science

AIDS, Supplement

Volumn 10, Issue 3, 1996, Pages

  Birx, Deborah L ^a,c   VanCott, Thomas ^b   Michael, Nelson ^a   McNeil, John ^a   Stamatos, Nicholas ^a   Gilliam, Bruce ^b   Davis, Rachel ^b   Carr, Jean ^b   McCutchan, Francine ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c NONE   (United States)

Author keywords

AIDS; Basic science; HIV 1

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

AIDS VACCINES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0029824959     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (150)

1. Cheng-Mayer C, Luciw PA: Immunopathogenesis in rhesus macaques infected with SIV/HIV-1 (SHIV) recombinant virus. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA401].
2. Yoshio K, Tanaka Y, Tanaka R, et al.: HIV-1 viremia model in hupbl-nod-scid mice. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3005].
3. Wathen LK, Nuorala KW, Patel RK, et al.: Validation of a quantitative DNA PCR assay for HIV-1 in human peripheral blood mononuclear cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA520].
4. Bremer JW, Brambilla D, Reichelderfer P: HIV RNA copy number estimates by PCR based amplification assays that use serial dilution of amplicon prior to detection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA522].
5. Izopet J, Bargues G, Bocket-Mouton L, et al.: Multicenter quality control of plasma HIV-1 RNA quantitation by a standardized reverse-transcriptase PCR assay. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA523].
6. Mulder J, McKinney N, Kwok S: A rapid and simple sample preparation method dramatically increases sensitivity of HIV-1 plasma RNA assay. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB914].
7. Weverling GJ, de Jong MD, Lange JMA, de Weerdt H, Goudsmit J, de Wolf F: Comparative analysis of serum HIV-1 RNA load in ZDV-treated individuals as measured by two quantitative assays. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB412].
8. Bürgisser P, Spertini F, Suter C, Pagani J-L, Meylan P: Monitoring the effects of antiretroviral treatment in lymph nodes by fine needle aspiration of lymph node cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract THB4329].
9. Dunne AL, Crowe SM: Comparison of branched chain DNA and RT-PCR for quantifying six different HIV-1 subtypes in plasma. XI International Conference on AIDS. Vancouver, July 1996 [abstract LBA6005].
10. Gleeson T, Montpetit M: Limited detection of HIV-1 subtypes by the Roche amplicor diagnostic polymerase chain reaction assay. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA160].
11. Christopherson CD, Kwok S: The effects of mutations on HIV-1 quantitation by RT/PCR. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA161].
12. Constantine NT, Mohamed A-H, Zhang X, Sangare A, HolmHansen C: Multi-center evaluation of an HIV-1/2 rapid assay in 9 countries and using seroconversion panels. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA151].
13. Hideakira Y, Hamamoto H, Fujii T, et al.: A new approach for HIV diagnosis: HIV can be detected directly. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA4046].
14. Fransen K, Nys P, Stynen D, Nkengasong J, van der Groen G: Comparison of two antigen tests: the Innotest HIV antigen mAb (Innogenetics) and Coulter HIV-1 p24 antigen assay. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA4047].
15. Louwagie J, Garrett PE, Mertens G, et al.: Sensitive HIV antigen assay detecting HIV-1 group M, HIV-1 group O and HIV-2 core proteins. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA162].
16. Ho D: Pathogenesis: resolved that viral factors, and not host factors, are the primary determinants of pathogenesis (affirmative). XI International Conference on AIDS. Vancouver, July 1996 [abstract Th19].
17. Pantaleo G: Pathogenesis: resolved that viral factors, and not host factors, are the primary determinants of pathogenesis (negative). XI International Conference on AIDS. Vancouver, July 1996 [abstract Th20].
18. Sheppard HW, Krowka J, Ascher M, Cuevas B, Dondero D, Lu E: Determinants of long-term non-progression: the relative contribution of viral burden and strain variation. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA390].
19. Pantaleo G, Soudeyns H, Demarest, et al.: Mechanisms of human immunodeficiency virus (HIV) escape from the immune response during primary infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA381].
20. Soudeyns H, Demarest JF, Vaccarezza M, et al.: Longitudinal analysis of T cell receptor chain clonal diversity during acute HIV infection: molecular and cellular approaches. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA380].
21. Musey LK, Hu Y-X, Schacker T, Hughes J, Corey L, McElrath MJ: Cellular immune responses in peripheral blood and lymph nodes during early HIV-1 infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA382].
22. Deng H, Liu R, Ellmeier W, et al.: Identification of C-C chemokine receptor 5 as the major coreceptor for entry of macrophage tropic human immunodeficiency virus type 1. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA927].
23. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877.
24. Deng H, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
25. Dragic T, Litwin V, Allaway CP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
26. Coffin JM: HIV viral dynamics. XI International Conference on AIDS. Vancouver, July 1996 [abstract Th18].
27. Gilliam BL, Dyer J, Cohen MS, Fiscus S, Eron JJ Jr: Effects of reverse transcriptase inhibitor therapy on HIV-1 viral burden in semen. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA1083].
28. Trono D: The multifaceted role of nef in HIV replication. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA490].
29. Miller MD, Warmerdam MW, Benitez B, Greene WC: HIV-1 nef enhanced of viral infectivity is correlated with its incorporation into virions and its cleavage by the HIV-1 protease. XI International Conference on AIDS. Vancouver, July 1996 [abstract THA921].
30. Solomon A, Smith K, Ludford-Menting M, et al.: Genomic defects in attenuated HIV-1 from the Sydney bloodbank long-term non-progressors. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA1033].
31. Martin I, Schaal H, Scheid A, Ruysschaert JM: Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA156].
32. Chelucci C, Federico M, Guerriero R, et al.: Productive human immunodeficiency virus infection of highly purified megakaryocytic precursors and mature megakaryocytes. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2043].
33. Toniolo A, Conaldi PG, Biancone L, et al.: Effects of HIV-1 and viral glycoproteins on glomerular and tubular renal cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2044].
34. Hiroshi K, Sekigawa I, Takeda N, et al.: Vesnarinone inhibits TNF-a-medialed T cell activation induced by HIV-1 gp120-bound macrophage. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3091].
35. Patke CL, Green C, Shearer W: Recombinant gp120 enhances cytokine-induced B lymphocyte activation and differentiation from seronegative donors. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3097].
36. Taoufik Y, Wallon C, Delfraissy JF: HIV gp120 inhibits the expression of IL-12 p35 and p40 sub-units by inducing the production of IL-10. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3083].
37. Tateyama M, Hattori M, Oishi T, Miyasaka S, Ohmoto Y, Fukutake K: Recombinant gp120 of HIV-1 induces soluble TNF receptor and TNF-α in peripheral mononuclear cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3089].
38. Haas G, Hosmalin A, Duntze J, et al.: Evolution of HIV-1 reverse transcriptase specific cytotoxic T cells (CTL) with disease progression and anti-retroviral therapy. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA282].
39. Musey LK, Hu Y-X, Schacker T, Hughes J, Corey L, McElrath MJ: Cellular immune responses in peripheral blood and lymph nodes during early HIV-1 infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA382].
40. Lewis D, Rahmati S, Yang L, et al.: Mechanisms of CD8+ T cell dysfunction in HIV. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA381].
41. Korn-Müller AC, Nitschko H, Gelderblom H, von der Helm K: Exposure of non-matured, non-infectious HIV particles to CD4 positive cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA262].
42. Margolick JB, Rinaldo CR, Gupta P, Farzadegan H, Mullins JI: Temporal relationship of changes in HIV load, HIV diversity, and cellular immunity to inflection points of CD4+ and CD3+ T cells in HIV-infected homosexual men. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA404].
43. McDonald JM, Pan G, Zhou T, Mountz J, Radding W, Saag M: Calmodulin antagonists inhibit spontaneous apoptosis of CD4+ cells from HIV+ infected patients. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2038].
44. Nardelli B, Gonzalez CJ, Valentine FT: The rapid induction of apoptosis in uninfected CD4 lymphocytes by HIV-infected cells occurs without formation of syncytia. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2041].
45. Shearer GM: Antigen-stimulated apoptotic T cell death: a model for CD4+ T cell depletion in HIV-1 infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA501].
46. Bentwich ZV, Kalinkovich Z, Weisman Z, Grossman Z: Persistent immune activation and the pathogenesis of AIDS: lessons from the Ethiopian immigration to Israel. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA503].
47. Gallo RC: Novel biological means of control of HIV and AIDS. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA260].
48. Weissman D: Role and potential mechanisms of action of chemokines in HIV replication. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA502].
49. Poli G, Ghezzi S, Alfano M, Vicenzi E: Suppression of HIV-1 replication by RANTES occurs at an early pre-integration level. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA501].
50. Dragic T, Litwin V, Allaway GP, et al.: β-Chemokines inhibit HIV-1 entry into CD4+ cells via the C-C CKR-5 co-receptor. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA275].
51. Garzino-Demo A, Gallo RC, DeVico AL, Cocchi F, Lusso P, Arya Suresh K: On the mechanism of C-C chemokines (RANTES, MIP-1α and MIP-1β) mediated inhibition of HIV. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA394].
52. Sharpe SA, Whatmore AM, Cook N, et al.: SIV-superinfection immunity in macaques is influenced by the dose of attenuated virus. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA400].
53. Scala E, Aiuti F, Rosso R, D'Offizi GP, Ferrara R, Paganelli R: Raised production of C-C chemokines by CD8+ T cells of long term non-progressor HIV-infected subjects. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA393].
54. Mackewicz CE, Barker E, Orque R, Levy JA: CD8+T cell-mediated suppression of HIV replication: relevance of known chemokines and other cytokines. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA390].
55. Copeland KFT, Leith J, Kelleher L, Smaill F, Rosenthal KL: CD8 T lymphocyte-mediated suppression of HIV-1 LTR-mediated transcription shows no correlation with clinical stage of disease or health status. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA395].
56. Levy JA, Mackewicz C, Barker E, Stranford S: Chemokines and HIV infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA503].
57. Fauci AS: Host factors in the pathogenesis of HIV disease. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB290].
58. Rubbert A, Weissman D, Daucher J, et al.: Effect of MIP-1α, MIP-1β and RANTES on suppression of HIV replication in T cell blasts and dendritic cell/CD4+ T cell cocultures. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA391].
59. Mann DL, Kaslow R, Goedert JJ, Nelson G: HLA class I peptide motif frequency in HIV-1 proteins correlates with the alleles association with disease progression. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA283].
60. Li J-J, Friedman-Kien AE, Huang YQ, Zhang WG, Feiner D: Detection of HHV-8 in subsets of blood cells from patients with AIDS-related Kaposi's sarcoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA163].
61. Klaskala W, Sosa C, Benetucci J, Wood C, Baum MK: Herpes virus and AIDS related Kaposi's sarcoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA164].
62. Briz M, Martin T, Yebra M, et al.: Detection of Kaposi sarcoma associated herpesvirus in skin lesions and peripheral blood of HIV-infected individuals. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA165].
63. Huang Y-O, Li JJ, Feiner D, et al.: Detection of HHV-8 in tissues of various organs from AIDS-KS patients. XI International Conference on AIDS. Vancouver, July 1996 abstract [WeA166].
64. Friedman-Kien AE, Li JJ, Jensen P, Huang YQ: Herpes-like virus (HHV-8) DNA sequences in various types of immunocompromised patients with Kaposi's sarcoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA167].
65. Guo HG, Colombini S, Raffeid M, et al.: Molecular characterization of HHV8 DNA sequences from an AIDS-related body cavity lymphoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA270].
66. Biberfeld P, Ekman M, Kaaya EE, Jagdahl L, Linde A, Biberfeld G: HHV8 and other herpes virus in AIDS related and endemic Kaposi's sarcoma (KS) and malignant lymphoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA272].
67. Buonaguro FM, Beth-Giraldo E, Tornesello ML, et al.: HHV-8 and other DNA virus sequences in endemic (African), classic, iatrogenic epidemic Kaposi's sarcoma biopsies. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA271].
68. Gao SJ, Kingsley L, Hoover D, et al.: Anti-KSHV antibody seroconversion in patients with AIDS. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA274].
69. Blackbourn DJ, Ambroziak JA, Lennette ET, et al.: The infectious nature of the novel herpesvirus-like DNA sequences detected in Kaposi's sarcoma. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA273].
70. Wainberg MA, Hsu M, Gu Z, Inouye P, Quan Y: Enhanced fidelity of 3TC-selected M184V HIV reverse transcriptase. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA380].
71. Prasad VR, Drosopoulos W: Mutations associated with 3TC-resistance enhance the polymerase fidelity of HIV-1 RT. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA381].
72. Boucher C: Reduced replication rate conferred by mutations at codon 184 in peripheral blood mononuclear cells. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA384].
73. Tanaka M, Mimoto T, Anderson B, et al.: Identification of protease inhibitors containing allophenylnorstatine active against both wild-type and KNI-272-resistant HIV-1 variants. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA260].
74. Ussery MA, Wood O, Broud D, et al.: The protease inhibitor KNI-272 inhibits HIV-1 infection in vivo in the HuPBMC-SCID mouse model. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA262].
75. Thaisrivongs S, Aristoff PA, Tarpley WG, et al.: The dihydropyrones: third-generation, non-peptidic HIV protease inhibitor development candidates. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA261].
76. Poppe SM, Slade D, Chong K, et al.: HIV-1 resistant to multiple peptidemimetic protease inhibitors lacks significant cross-resistance to the dihydropyrone inhibitors. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA153].
77. Johns DG, Driscoll J: 2′-β-fluoro-2′,3′-dideoxyadenosine (F-DDA): a new anti-HIV clinical drug candidate. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA1076].
78. Black PL, Wood O, Broud D, et al.: T-20, a novel inhibitor of HIV-1 fusion, blocks recovery of infectious HIV-1 and inhibits viral load in vivo in the HuPBMC-SCID mouse model. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA263].
79. Robinson WE, Chow SA, Reinecke MG: New antiretroviral agents with activity against HIV and FIV integrase. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA264].
80. Harvie P, Dusserre N, Desormeaux A, Tremblay M, Beauchamp D, Bergeron MG: Targeting lymphoid organs in HIV disease. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA155].
81. Portmore AC, Haga-Rice J, Pesano RL, McShane DJ, Lipil WH: CD4 response and adverses reactions to monthly subcutaneous interleukin-2 in HIV-infected pts. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3101].
82. Davey RT, Chaitt D, Kovacs J, et al.: Subcutaneous interleukin-2 therapy is capable of inducing marked sustained increases in CD4 counts in early HIV-infected patients. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB290].
83. -1. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB292].
84. Skolnik PR, Wang A, Fabry J, Lieberman J: IL-15 supports anti-HIV-1 cytotoxic T cell and NK activity with less induction of HIV-1 replication than IL-2. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA141].
85. 6/I. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA3094].
86. St Louis DC, Levine B, Mosca J, et al.: Antiviral effect from the CD28 costimulatory receptor mediates ex vivo CD4+ T cell expansion from patient with HIV-1 infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA271].
87. Levine BL, Mosca JD, Riley JL, et al.: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996, 272:1939-1943
88. Johnson RP, Rosenzweig M, Marks DF, Heusch M, Wong-Staal F: Hematopoietic stem cell therapy with a SIV-specific ribozyme protects T cells and macrophages from SIV infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA272].
89. Bauer G, Wen SF, Bahner I, Kearns K, Zaia J, Kohn DB: Inhibition of HIV-1 replication in anti HIV-1 gene expressing long term bone marrow cultures established from CD34+ cells of HIV-1 infected donors. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA271].
90. Richman D: Roundtable: recent developments in antiviral resistance: an overview of the Whistler Meeting. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB400].
91. Kalinkovich A, Weisman Z, Nahmias J, et al.: Host immunity but not HIV-1 type is a major cofactor for HIV infection in Africa. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA165].
92. Blackbourn DJ, Mackewicz CE, Barker E, et al.: CD8+ cell suppression of HIV occurs in lymphoid tissues as well as in peripheral blood of HIV-infected individuals. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA102].
93. Fevrier M, Buseyne F, Schwartz O, Stevanovic S, Rammensee H-G, Riviere Y: Dual activity of a human CTL clones: cytotoxic activity and control of virus replication. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA103].
94. Kalams SA, Harrer T, Harrer E, et al.: HIV-1-specific cytotoxic T lymphocyte and proliferative responses in peripheral blood mononuclear cells (PBMC) of subjects with stable non-progressing HIV-1 infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA391].
95. Lubaki MN, Dhruva B, Quinn TC, Siliciano RF, Bollinger RC: Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in individuals without clinical progression. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA392].
96. Hadida F, Bonduelle O, Candotti D, et al.: Immunological studies on the french cohort of 70 HIV-1-infected long-term non progressors (LTNP). XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA393].
97. Klucking S, Robertson MN, Looney D, et al.: Transient, low level infection of macaques with HIV-2 is able to induce virus-specific CTL. XI International Conference on AIDS. Vancouver, July 1996 [abstract THA142].
98. Fatim C, Ariyoshi K, O'Donovan D, et al.: Cylotoxic T lymphocyte activity in HIV-2 seropositive mothers and their 9 month old infants. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA143].
99. Klein MR, Pontesilli O, Holwerda AM, Kerkhof-Garde SR, de Wolf F, Miedema F: Kinetics of HIV-1 specific CTL during the clinical course of HIV-1 infection: further evidence for a general collapse of cellular immunity. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA281].
100. Autran B, Gomard E, Riviere Y, Agut H, Bouley JM, Katlama C: Prospective follow-up studies of HIV-specific cytotoxic T lymphocytes (CTL) in a french cohort of 150 patients: Immunoco. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA280].
101. Kent SJ, Greenberg P, Hoffman M, Corey L, McElrath MJ: Antagonism of vaccine-induced HIV-specific CD4+ T cells by primary HIV infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA405].
102. Rungruengthanakit K, Duerr A, Suriyanon V, et al.: Immune parameters among highly exposed, persistently seronegative (HEPS) Thai women. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA401].
103. Krowka JF, Allen S, Weinstein S, et al.: Are high-risk HIV-seronegative Zambian women resistant or just lucky? XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA402].
104. Heeney JL, Bogers WMJM, Mooij P, Teeuwsen V: Immune correlates of protection in HIV vaccine efficacy trials in nonhuman primates. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA404].
105. Stamatos NM, VanCott TC, Mascola J, Loomis LD, Louder M, Birx DL: Removal of V3-specific antibodies from the serum of infected patients has minimal effect on neutralization of primary isolates of clade E HIV-1. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA271].
106. Pinter A, Honnen WJ, Wu Z, Troshev O, Kayman SC: Antibodies in human sera to highly conserved epitopes in the V1/V2 domain of gp120 that mediate potent neutralization of macrophagetropic HIV-1 isolates. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2101].
107. Zolla-Fazner S, Berman P, Gregory T, et al.: Induction of primary isolate-neutralizing antibodies by candidate HIV-1 vaccines. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA406].
108. Nyambi PN, Lewi P, Nkengasong J, et al.: Cross-clade neutralization of HIV-1 by homologous and heterologous sera and identification of three isolates that predicts the neutralizing capacity of sera across HIV-1 clades. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA273].
109. Nara PL, Merges M, Wu S-C, Spouge J: Plasma factors in human blood alter the entry and neutralization properties of HIV-1: implications for gp120-based vaccine approaches. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA270].
110. Parren PWHI, Fisicaro P, Barbas CF III, Burton DR: Inactivation of HIV-1 by recombinant antibodies. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA274].
111. Graham BS, for the NIAID AIDS Vaccine Clinical Trials Network: Phase I/II evaluation of candidate AIDS vaccines. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA280].
112. Clements ML, Weinhold K, Siliciano R, et al.: HIV immunity induced by canarypox (ALVAC)-MN gp160, -SF2 rgp120 or both. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA281].
113. Fukushima J, Hamajima K, Asakura Y, et al.: Efficacy of a DNA vaccination to induce neutralizing antibody and cytotoxic cells against HIV-1. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA150].
114. Hamajima K, Fukushima J, Kaneko T, et al.: The combination of DNA and peptide vaccines induces strong immunities against HIV-1 in both humoral and CMI. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA151].
115. Wahren B, Hinkula J, Benthin R, et al.: Induction of immune responses by DNA of HIV-1 regulatory and structural genes. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA523].
116. Corey L, Weinhold K, McElrath J, et al.: AVEU 022: safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 in seronegative adult volunteers. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA282].
117. Lu Y, Touzjian N, Kushner N, et al.: HIV-1 secreted viral antigens (SVA), polyphosphazene adjuvant, and SHIV challenge model. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA520].
118. Wagner R, Teeuwsen V, Deml L, Heeney J, Wolf H: Immunogenicity of modified, recombinant HIV-1 virus-like particles in rhesus monkeys. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoAS21].
119. Ludwig D, Schirmbeck R, Reimann J, Wolf H, Wagner R: HIV-1 PR55gag virus-like particles allow the access of polyproteins and defined epitopes to the MHC-1 presentation-pathway. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA156].
120. Mitchell WM, Ding L, Baird C: Induction of mucosal and systemic immune response to HIV gp160 by genetic vaccination. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA390].
121. VanCott TC, Kaminski R, Lewis M, et al.: Mucosal and systemic immune responses to parenteral and intranasal administration of an oligomeric HIV-1 gp160 vaccine. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA391].
122. Polacino P, Stallard V, Klaniecki J, et al.: Immunization with SIVmne envelope (gp160) vaccines protected macaques against intrarectal challenge by uncloned virus. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA103].
123. Girard M, Barre-Sinoussi F, Tartaglia J, et al.: Immunization with an HIV-1 canarypox virus recombinant confers protection against genital HIV-1 challenge in chimpanzees. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA393].
124. Malamud D, Douglas A, Rest R: Microbicidal activity of C31G against N. gonorrhoeae under conditions that mimic the in vivo situation. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA510].
125. Bergeron MG, Gagne N, Gourde P, et al.: Microbicidal gel to prevent the sexual transmission of HIV. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA512].
126. Bourinbaiar AS, Fruhstorfer EC, Lopes R: The effect of gramicidin, microbicide and spermicide, against HIV and herpes virus infections. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA513].
127. Berman PW, Gray A, Ashby M, et al.: Genetic and immunologic characterization of viruses infecting MN-rgp120 vaccinated volunteers. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA285].
128. Mbidde EK: HIV vaccines: resolved that more fundamental research on vaccine development is required prior to the implementation of phase III trials of HIV vaccines (negative). XI International Conference on AIDS. Vancouver, July 1996 [abstract-Tu09].
129. Moore J: HIV vaccines: resolved that more fundamental research on vaccine development is required prior to the implementation of phase III trials of HIV vaccines (affirmative). XI International Conference on AIDS. Vancouver, July 1996 [abstract Tu10].
130. Liitsola K, Laukkanen T, Salminen M: Several genetic subtypes of HIV-1 found in the areas around the Baltic Sea. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2058].
131. Morgado MG, Guimaraes ML, Gripp CBG: HIV-1 diversity in patients from Rio de Janeiro, Brazil. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA103].
132. Dietrich U, Ruppach H, Gehring S, et al.: V3-based PE1A for Serodifferentiation of HIV types and subtypes: non-B HIV-1 subtypes contribute to the epidemic in Germany, Spain and Israel. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA105].
133. Subbarao S, Limpakarnjanarat K, Bhumisawasdi J, et al.: Genetic diversity of HIV-1 in Thailand, 1994-95. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA375].
134. Sullivan PS, Simon P, Ward JW, et al.: Identification of group O HIV infection in the United States. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA922].
135. Takehisa J, Zekeng L, Miura T, et al.: Phylogenetic analysis of HIV-1/2 in Cameroon based on the pol and env regions: evidence of mixed-infection. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA372].
136. Williamson C, Engelbrecht S, van Harmelen J, van Rensburg EJ, Bredell W, Wood R: Distinct HIV-1 subtypes associated with different risk groups in South Africa. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA101].
137. Robbins KE, Jaffe HW, Schable CA, et al.: Comparison of HIV-1 sequences from 1981 with more current isolates in the United States epidemic. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA102].
138. McCutchan FE, Salminen MO, Carr JK, et al.: Breakpoints in the full-length genomes of intergenotypic recombinants of HIV-1 and their functional implications. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2077].
139. Carr JK, Salminen MO, Leinikki P, Johansson B, Burke DS, McCutchan FE: First full length sequence prototypes of HIV-1 clades C, E and C: two of three are mosaic genomes. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA100].
140. Salminen MO, Robertson DL, Sharp PM, Hahn BH, Burke DS, McCutchan FE: Continuous in vivo recombination between HIV-I strains of genetic subtypes A and C. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA511].
141. Fultz PN, Wei Q, Yue L, Barre-Sinoussi F, Girard M: In vivo recombination between two HIV-1 strains from different clades following superinfection of chimpanzees. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA510].
142. Nyambi PN, Willems B, Nkengasong J, et al.: Antigenic and biologic properties of recombinant HIV-1 isolates. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2047].
143. Nyambi PN, Willems B, Nkengasong J, et al.: Antigenic and biologic properties of recombinant HIV-1 isolates. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2047].
144. Lasky M, Perret JL, Peeters M, et al.: The impact of the HIV-1 genetic subtype on the natural history of HIV-1 infection: preliminary results. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2060].
145. Kalish ML, Wiener P, Nesheim S, et al.: Detection of phylogenetically linked HIV strains among a population of epidemiologically unrelated women. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA2078].
146. Soto-Ramirez LE, Renjifo B, Marlink R, McLane MF, Essex M: Differential growth of HIV-1 subtypes in Langerhans' cells, relation to transmission route. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA370].
147. Mbidde EK: The role of developing countries in research and development and testing of HIV vaccines. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThA285].
148. Myers G, Korber B, Hahn BH, et al.: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 1995.
149. Carr JK, Salimen MO, Gotte D, Koch C, Burke DS, McCutchan FE: Mosaic structure of the full-length genome from a human immunodeficiency virus type 1 isolate of clade E from Thailand. J Virol 1996, 70:5933-5943.
150. Gao F, Robertson DL, Morrison SG, et al.: The heterosexual HIV-1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996, 70:7013-7029.